Literature DB >> 16153758

Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations.

Randall J Basaraba1, Angelo A Izzo, Lise Brandt, Ian M Orme.   

Abstract

The BCG vaccine for tuberculosis has an outstanding safety record, with only occasional reports of adverse reactions. In some countries multiple BCG vaccinations have been given to children, but with no apparent benefit. We show here that in the highly susceptible guinea pig model of Mycobacterium tuberculosis infection animals receiving three sequential injections of BCG began to die unexpectedly at times after aerosol challenge much earlier than animals receiving the vaccine only once. Animals receiving three injections with BCG had extensive, disseminated lesions in the lungs, spleen and liver that were similar to non-vaccinated animals. In these animals there was effacement of the pulmonary, hepatic and splenic architecture by extensive areas of fibrosis with residual granulomatous inflammation and necrosis. This contrasted to the saline control group in which active inflammation was accompanied by extensive areas of necrosis but with less fibrosis in the lungs and spleen. Granulomatous inflammation was less severe and was not complicated by necrosis or extensive fibrosis in animals receiving a single injection with BCG. These data indicate that multiple BCG vaccination, which is akin to super-infection with the living vaccine, leads to major organ failure pathology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16153758     DOI: 10.1016/j.vaccine.2005.07.103

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Drug treatment combined with BCG vaccination reduces disease reactivation in guinea pigs infected with Mycobacterium tuberculosis.

Authors:  Shaobin Shang; Crystal A Shanley; Megan L Caraway; Eileen A Orme; Marcela Henao-Tamayo; Laurel Hascall-Dove; David Ackart; Ian M Orme; Diane J Ordway; Randall J Basaraba
Journal:  Vaccine       Date:  2012-01-11       Impact factor: 3.641

2.  Mycobacterial shuttle vectors designed for high-level protein expression in infected macrophages.

Authors:  Jennifer L Eitson; Jennifer J Medeiros; Ashley R Hoover; Shashikant Srivastava; Kole T Roybal; José A Aínsa; Eric J Hansen; Tawanda Gumbo; Nicolai S C van Oers
Journal:  Appl Environ Microbiol       Date:  2012-07-20       Impact factor: 4.792

3.  Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity.

Authors:  Dongmei Lu; Lucila Garcia-Contreras; Pavan Muttil; Danielle Padilla; Ding Xu; Jian Liu; Miriam Braunstein; David N McMurray; Anthony James Hickey
Journal:  AAPS J       Date:  2010-04-27       Impact factor: 4.009

4.  Deciphering the proteome of the in vivo diagnostic reagent "purified protein derivative" from Mycobacterium tuberculosis.

Authors:  Yun Sang Cho; Karen M Dobos; Jessica Prenni; Hongliang Yang; Ann Hess; Ida Rosenkrands; Peter Andersen; Sung Weon Ryoo; Gill-Han Bai; Michael J Brennan; Angelo Izzo; Helle Bielefeldt-Ohmann; John T Belisle
Journal:  Proteomics       Date:  2012-04       Impact factor: 3.984

5.  A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.

Authors:  Sylvie Bertholet; Gregory C Ireton; Diane J Ordway; Hillarie Plessner Windish; Samuel O Pine; Maria Kahn; Tony Phan; Ian M Orme; Thomas S Vedvick; Susan L Baldwin; Rhea N Coler; Steven G Reed
Journal:  Sci Transl Med       Date:  2010-10-13       Impact factor: 17.956

6.  Therapeutic vaccination against relevant high virulence clinical isolates of Mycobacterium tuberculosis.

Authors:  Crystal A Shanley; Gregory C Ireton; Susan L Baldwin; Rhea N Coler; Steven G Reed; Randall J Basaraba; Ian M Orme
Journal:  Tuberculosis (Edinb)       Date:  2013-09-07       Impact factor: 3.131

7.  Post-exposure vaccination against Mycobacterium tuberculosis.

Authors:  Marcela Henao-Tamayo; Gopinath S Palaniswamy; Erin E Smith; Crystal A Shanley; Baolin Wang; Ian M Orme; Randall J Basaraba; Nancy M DuTeau; Diane Ordway
Journal:  Tuberculosis (Edinb)       Date:  2009-03-04       Impact factor: 3.131

8.  Increased expression of host iron-binding proteins precedes iron accumulation and calcification of primary lung lesions in experimental tuberculosis in the guinea pig.

Authors:  Randall J Basaraba; Helle Bielefeldt-Ohmann; Ellie K Eschelbach; Claire Reisenhauer; Airn E Tolnay; Lauren C Taraba; Crystal A Shanley; Erin A Smith; Cathy L Bedwell; Elizabeth A Chlipala; Ian M Orme
Journal:  Tuberculosis (Edinb)       Date:  2007-10-17       Impact factor: 3.131

9.  Evaluation of Peripheral Blood Markers as Early Endpoint Criteria in Guinea Pigs (Cavia porcellus) when Testing Tuberculosis Vaccine Candidates.

Authors:  Wendy R Williams; JoLynn Troudt; Elizabeth Creissen; Helle Bielefeldt-Ohmann; Matthew S Johnston; Lon V Kendall; Angelo A Izzo
Journal:  Comp Med       Date:  2020-01-17       Impact factor: 0.982

10.  Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis.

Authors:  Zhou Xing; Christine T McFarland; Jean-Michel Sallenave; Angelo Izzo; Jun Wang; David N McMurray
Journal:  PLoS One       Date:  2009-06-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.